Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03375567 · ClinicalTrials.gov registry record · NA
Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT03375567 is a NA study that has completed, run by Yale University. The registered enrollment target is 28 participants.
The verdict
NCT03375567, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the detection rate of residual/refractory disease based on standard bone marrow biopsy versus guided myeloma lesion biopsy after induction therapy with carfilzomib, lenalidomide and dexamethasone regimen.
Interventions
- PROCEDURE Guided Lesion Biopsies
- PROCEDURE Standard Lesion Biopsies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2022-01-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03375567
The ClinicalTrials.gov registry entry for NCT03375567 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guided Lesion Biopsies is the first listed.
NCT03375567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03375567 about?
NCT03375567 is a clinical study titled "Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone". The primary objective of this study is to compare the detection rate of residual/refractory disease based on standard bone marrow biopsy versus guided myeloma lesion biopsy after induction therapy with carfilzomib, lenalidomide and dexamethasone regimen.
What is the current status of trial NCT03375567?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2018-06-04. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT03375567?
The interventions under investigation include: Guided Lesion Biopsies (PROCEDURE), Standard Lesion Biopsies (PROCEDURE).
Who is sponsoring clinical trial NCT03375567?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.